| Outcome Measures: |
Primary: Change from baseline in Glycosylated Hemoglobin (HbA1c), Baseline, 24 weeks | Secondary: Change from baseline in Glycosylated Hemoglobin (HbA1c), Baseline, 52 weeks|Change from baseline in Fasting plasma glucose, Baseline, 24 weeks, 52weeks|Change from baseline in HOMA-IR(Homeostasis Model Assessment of Insulin Resistance), Baseline, 24 weeks, 52weeks|Change from baseline in HOMA-β(Homeostasis Model Assessment of β-cell function), Baseline, 24 weeks, 52weeks|Change from baseline in QUICKI(Quantitative Insulin Check Index), Baseline, 24 weeks, 52weeks|HbA1c target achievement rate at 24, 52weeks(HbA1c < 6.5%, 7%), Baseline, 24 weeks, 52weeks|Change from baseline in Total Cholesterol, Baseline, 24 weeks, 52weeks|Change from baseline in Triglycerides, Baseline, 24 weeks, 52weeks|Change from baseline in LDL-Cholesterol, Baseline, 24 weeks, 52weeks|Change from baseline in HDL-Cholesterol, Baseline, 24 weeks, 52weeks|Change from baseline in non-HDL-Cholesterol, Baseline, 24 weeks, 52weeks|Change from baseline in Small Dense LDL-Cholesterol, Baseline, 24 weeks, 52weeks|Change from baseline in FFA(Free Fatty Acid), Baseline, 24 weeks, 52weeks|Change from baseline in Apo-AⅠ, Baseline, 24 weeks, 52weeks|Change from baseline in Apo-B, Baseline, 24 weeks, 52weeks|Change from baseline in Apo-CⅢ, Baseline, 24 weeks, 52weeks|Evaluate safety of CKD-501 from number of participants with adverse events, Baseline, 24 weeks, 52weeks
|
